Pfizer’s Vyndaqel Success Interfering With Alnylam's Plans
Blockbuster Status In Sight For Pfizer Drug
Alnylam wants to emulate success of Eylea and Revlimid in amyloidosis– but Pfizer could spoil the plan.
You may also be interested in...
Givosiran was approved by the US FDA for the treatment of acute hepatic porphyria, a rare generic blood disorder, nearly three months ahead of the action date.
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.